Description
Ibrutix (Imbruvica) Ibrutinib 140mg Online
Ibrutix (Imbruvica) Ibrutinib is a medicine that targets proteins in cancer cells and stops the cancer cells from growing.
It is used to treat mantle cell lymphoma, chronic lymphocytic leukemia, small lymphocytic lymphoma, marginal zone lymphoma, Waldenstrom macroglobulinemia, and chronic graft-versus-host disease.
Ibrutix is used to treat cancers such as leukemia, breast cancer, melanoma, lung cancer, and renal cancer. They are also used in the treatment of rheumatoid arthritis and to prevent organ transplant rejection. They work by stopping cancer cell growth and preventing the spread of the cells. Ibrutinib is in a class of medications called kinase inhibitors.
It works by blocking the action of the abnormal protein that signals cancer cells to multiply. This helps stop the spread of cancer cells.
Ibrutix is used to treat people with mantle cell lymphoma (MCL; fast-growing cancer that begins in the cells of the immune system) who have already been treated with at least one other chemotherapy medication, people with chronic lymphocytic leukemia (CLL; a type of cancer that begins in the white blood cells) and small lymphocytic lymphoma (SLL; a type of cancer that begins mostly in the lymph nodes),
to treat people with Waldenstrom’s macroglobulinemia (WM; slow-growing cancer that begins in certain white blood cells in your bone marrow), people with marginal zone lymphoma (MZL; slow-growing cancer that begins in a type of white blood cells that normally fights infection) who have already been treated with a certain type of chemotherapy medication, and to treat people with chronic graft vs host disease (cGVHD; a complication of hematopoietic stem-cell transplant [HSCT; a procedure that replaces diseased bone marrow with healthy bone marrow] that may start a while after the transplant and last for a long time) after being treated unsuccessfully with 1 or more medications.
